An organic electroluminescence device includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region, wherein the hole transport region includes a polycyclic compound represented by Formula 1, and the device shows high emission efficiency:

##STR00001##

The present invention relates to an organic light emitting diode comprising: a first electrode; a second electrode facing the first electrode; a hole injecting layer or a hole transport layer, which is interposed between the first electrode and the second electrode; and a light emitting layer, wherein the hole injecting layer or the hole transport layer comprises at least one type of amine compound represented by chemical formula A or chemical formula B, and the chemical formula A and the chemical formula B are the same as those included in the description of the invention.

The present invention relates to heterocyclic compounds of formula (I) capable of activating STING (Stimulator of Interferon Genes).

##STR00001##

The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R.sup.4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis. The disclosure also includes pharmaceutical compositions containing a compound or salt of Formula I. ##STR00001##

The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R.sup.4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis. The disclosure also includes pharmaceutical compositions containing a compound or salt of Formula I. ##STR00001##

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

An organic electroluminescence device of an embodiment includes a first electrode, a second electrode provided on the first electrode, and a plurality of organic material layers provided between the first electrode and the second electrode, wherein at least one organic material layer among the plurality of organic material layers include a monoamine compound, and the monoamine compound includes a core structure including two condensed rings which are combined to form a spiro structure, where each condensed ring has a condensed structure of three or more pentagonal or hexagonal rings. High emission efficiency may be achieved.

An organic electroluminescence device of an embodiment includes a first electrode, a second electrode provided on the first electrode, and a plurality of organic material layers provided between the first electrode and the second electrode, wherein at least one organic material layer among the plurality of organic material layers include a monoamine compound, and the monoamine compound includes a core structure including two condensed rings which are combined to form a spiro structure, where each condensed ring has a condensed structure of three or more pentagonal or hexagonal rings. High emission efficiency may be achieved.

Disclosed are compounds of Formula (I)

##STR00001##

N-oxides, or salts thereof, wherein G, A, R.sub.1, R.sub.5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.